Update on prescription extended-release opioids and appropriate patient selection

References

• Institute of Medicine of the National AcademiesRelieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and ResearchWashingtonIOM2011 Available from: http://www.iom.edu/relievingpainAccessed October 12, 2011
   Google Scholar
• CroftPBlythFMvan der WindtDThe global occurrence of chronic pain: an introductionCroftPBlythFMvan der WindtDChronic Pain Epidemiology: From Aetiology to Public HealthOxfordOxford University Press2010918
   Google Scholar
• BreivikHCollettBVentafriddaVCohenRGallacherDSurvey of chronic pain in Europe: prevalence, impact on daily life, and treatmentEur J Pain20061028733316095934
   PubMed Web of Science ®Google Scholar
• CiceroTJSurrattHLKurtzSEllisMSInciardiJAPatterns of prescription opioid abuse and comorbidity in an aging treatment populationJ Subst Abuse Treat201242879421831562
   PubMed Web of Science ®Google Scholar
• NicholsonBBenefits of extended-release opioid analgesic formulations in the treatment of chronic painPain Pract20089718119019047
   PubMed Web of Science ®Google Scholar
• GurejeOVon KorffMSimonGEGaterRPersistent pain and well-being: a World Health Organization study in primary careJAMA19982801471519669787
   PubMed Web of Science ®Google Scholar
• GurejeOSimonGEVon KorffMA cross-national study of the course of persistent pain in primary carePain20019219520011323140
   PubMed Web of Science ®Google Scholar
• BreuerBCrucianiRPortenoyRKPain management by primary care physicians, pain physicians, chiropractors, and acupuncturists: a national surveySouth Med J201010373874720622716
   PubMed Web of Science ®Google Scholar
• KuehnBMOpioid prescriptions soar: increase in legitimate use as well as abuseJAMA200729724925117227967
   PubMed Web of Science ®Google Scholar
• MoskovitzBLBensonCJPatelAAAnalgesic treatment for moderate-to-severe acute pain in the United States: patient perspectives in the Physicians Partnering Against Pain (P3) surveyJ Opioid Manag2011727728621957827
   PubMedGoogle Scholar
• ManchikantiLSinghVDattaSCohenSPHirschJAComprehensive review of epidemiology, scope, and impact of spinal painPain Physician200912E35E7019668291
   PubMed Web of Science ®Google Scholar
• ManchikantiLAbdiSAtluriSAmerican Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part 2 – guidancePain Physician201215S67S11622786449
   PubMed Web of Science ®Google Scholar
• ChouRFanciulloGJFinePGClinical guidelines for the use of chronic opioid therapy in chronic noncancer painJ Pain20091011313019187889
   PubMed Web of Science ®Google Scholar
• American Geriatrics Society Panel on the Pharmacological Management of Persistent Pain in Older PersonsPharmacological management of persistent pain in older personsPain Med2009101062108319744205
   PubMed Web of Science ®Google Scholar
• McNicolEOpioid side effects and their treatment in patients with chronic cancer and noncancer painJ Pain Palliat Care Pharmacother20082227028121923311
   PubMedGoogle Scholar
• ChanBKBTamLKWatCYChungYFTsuiSLCheungCWOpioids in chronic non-cancer painExpert Opin Pharmacother20111270572021254859
   PubMed Web of Science ®Google Scholar
• ManchikantiLAilinaniHKoyyalaguntaDA systematic review of randomized trials for long-term opioid management for chronic non-cancer painPain Physician2011149112121412367
   PubMed Web of Science ®Google Scholar
• StannardCFOpioids for chronic pain: promise and pitfallsCurr Opin Support Palliat Care2011515015721430541
   PubMedGoogle Scholar
• AngstMSChuLFTingleMSShaferSLClarkJDDroverDRNo evidence for the development of acute tolerance to analgesic, respiratory depressant and sedative opioid effects in humansPain2009142172619135798
   PubMed Web of Science ®Google Scholar
• CiceroTJEllisMSEffect of abuse-deterrent formulation of OxyContinN Engl J Med201236718718922784140
   PubMed Web of Science ®Google Scholar
• WebsterLSt MarieBMcCarbergBPassikSDPanchalSJVothECurrent status and evolving role of abuse-deterrent opioids in managing patients with chronic painJ Opioid Manag2011723524521823554
   PubMedGoogle Scholar
• LeverenceRRWilliamsRLPotterMChronic non-cancer pain: a siren for primary care – a report from the Primary Care Multiethnic Network (PRIME Net)J Am Board Fam Med20112455156121900438
   PubMed Web of Science ®Google Scholar
• FischMJLeeJWWeissMProspective, observational study of pain and analgesic prescribing in medical oncology outpatients with breast, colorectal, lung, or prostate cancerJ Clin Oncol2012301980198822508819
   PubMed Web of Science ®Google Scholar
• PappagalloMIncidence, prevalence, and management of opioid bowel dysfunctionAm J Surg200118211S18S11755892
   PubMed Web of Science ®Google Scholar
• TrescotAMDattaSLeeMHansenHOpioid pharmacologyPain Physician200811S133S15318443637
   PubMed Web of Science ®Google Scholar
• ArgoffCESilversheinDIA comparison of long- and short-acting opioids for the treatment of chronic noncancer pain: tailoring therapy to meet patient needsMayo Clin Proc20098460261219567714
   PubMed Web of Science ®Google Scholar
• PortenoyRKSciberrasAEliotLLoewenGButlerJDevaneJSteady-state pharmacokinetic comparison of a new, extended-release, once daily morphine formulation, Avinza, and a twice-daily controlled-release morphine formulation in patients with chronic moderate-to-severe painJ Pain Symptom Manage20022329230011997198
   PubMed Web of Science ®Google Scholar
• CaldwellJRHaleMEBoydRETreatment of osteoarthritis pain with CR oxycodone or fixed combination oxycodone plus acetaminophen added to nonsteroidal antiinflammatory drugs: a double blind, randomized, multicenter, placebo controlled trialJ Rheumatol19992686286910229408
   PubMed Web of Science ®Google Scholar
• HagenNAThirlwellMEisenhofferJQuigleyPHarsanyiZDarkeAEfficacy, safety, and steady-state pharmacokinetics of once-a-day controlled-release morphine (MS Contin XL) in cancer painJ Pain Symptom Manage200529809015652441
   PubMed Web of Science ®Google Scholar
• CarsonSThakurtaSLowASmithBChouRDrug class review Long-acting opioid analgesics. Final update 6 reportPortland (OR)Oregon Health and Science University2011 Available from: http://www.ncbi.nlm.nih.gov/books/NBK62335Accessed September 14, 2012
   Google Scholar
• ColuzziFMattiaCOxycodone. Pharmacological profile and clinical data in chronic pain managementMinerva Anestesiol20057145146016012419
   PubMedGoogle Scholar
• BohnertASValensteinMBairMJAssociation between opioid prescribing patterns and opioid overdose-related deathsJAMA20113051315132121467284
   PubMed Web of Science ®Google Scholar
• FinePGMahajanGMcPhersonMLLong-acting opioids and short-acting opioids: appropriate use in chronic pain managementPain Med200910Suppl 2S79S8819691687
   PubMed Web of Science ®Google Scholar
• GourlayGKSustained relief of chronic pain. Pharmacokinetics of sustained release morphineClin Pharmacokinet1998351731909784932
   PubMed Web of Science ®Google Scholar
• ShramMJSathyanGKhannaSEvaluation of the abuse potential of extended release hydromorphone versus immediate release hydromorphoneJ Clin Psychopharmacol201030253320075644
   PubMed Web of Science ®Google Scholar
• SetnikBRolandCLClevelandJMWebsterLThe abuse potential of Remoxy, an extended-release formulation of oxycodone, compared with immediate- and extended-release oxycodonePain Med20111261863121463474
   PubMed Web of Science ®Google Scholar
• DuensingLEksterowiczNMacarioABrownMSternLOgbonnayaAPatient and physician perceptions of treatment of moderate-to-severe chronic pain with oral opioidsCurr Med Res Opin2010261579158520429822
   PubMed Web of Science ®Google Scholar
• HaleMKhanAKutchMLiSOnce-daily OROS hydromorphone ER compared with placebo in opioid-tolerant patients with chronic low back painCurr Med Res Opin2010261505151820429852
   PubMed Web of Science ®Google Scholar
• GordonACallaghanDSpinkDBuprenorphine transdermal system in adults with chronic low back pain: a randomized, doubleblind, placebo-controlled crossover study, followed by an open-label extension phaseClin Ther20103284486020685494
   PubMed Web of Science ®Google Scholar
• WildJEGrondSKuperwasserBLong-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis painPain Pract20101041642720602712
   PubMed Web of Science ®Google Scholar
• FriedmannNKlutzaritzVWebsterLLong-term safety of Remoxy (extended-release oxycodone) in patients with moderate to severe chronic osteoarthritis or low back painPain Med20111275576021481168
   PubMed Web of Science ®Google Scholar
• WallaceMThipphawongJOpen-label study on the long-term efficacy, safety, and impact on quality of life of OROS hydromorphone ER in patients with chronic low back painPain Med2010111477148821199302
   PubMed Web of Science ®Google Scholar
• PergolizziJAlonEBaronRTapentadol in the management of chronic low back pain: a novel approach to a complex condition?J Pain Res2011420321021887117
   PubMedGoogle Scholar
• ChaoJRetrospective analysis of Kadian (morphine sulfate sustained-release capsules) in patients with chronic, nonmalignant painPain Med2005626226515972090
   PubMed Web of Science ®Google Scholar
• MatsumotoAKBabulNAhdiehHOxymorphone extended-release tablets relieve moderate to severe pain and improve physical function in osteoarthritis: results of a randomized, double-blind, placebo- and active-controlled phase III trialPain Med2005635736616266356
   PubMed Web of Science ®Google Scholar
• GibofskyABarkinRLChronic pain of osteoarthritis: considerations for selecting an extended-release opioid analgesicAm J Ther20081524125518496262
   PubMed Web of Science ®Google Scholar
• KatzNSunSJohnsonFStaufferJAOL-01 (morphine sulfate and naltrexone hydrochloride) extended-release capsules in the treatment of chronic pain of osteoarthritis of the hip or knee: pharmacokinetics, efficacy, and safetyJ Pain20101130331119944650
   PubMed Web of Science ®Google Scholar
• FashnerJBellALHerpes zoster and postherpetic neuralgia: prevention and managementAm Fam Physician2011831432143721671543
   PubMed Web of Science ®Google Scholar
• MoulinDERicharzUWallaceMJacobsAThipphawongJEfficacy of the sustained-release hydromorphone in neuropathic pain management: pooled analysis of three open-label studiesJ Pain Palliat Care Pharmacother20102420021220718640
   PubMedGoogle Scholar
• HermannsKJunkerUNolteTProlonged-release oxycodone/naloxone in the treatment of neuropathic pain – results from a large observational studyExpert Opin Pharmacother20121329931122224497
   PubMed Web of Science ®Google Scholar
• VictorTWAlvarezNAGouldEOpioid prescribing practices in chronic pain management: guidelines do not sufficiently influence clinical practiceJ Pain2009101051105719595639
   PubMed Web of Science ®Google Scholar
• SloanPABarkinRLOxymorphone and oxymorphone extended release: a pharmacotherapeutic reviewJ Opioid Manag2008413114418717508
   PubMedGoogle Scholar
• Facts and Comparisons [homepage on the Internet] Available from: http://www.factsandcomparisons.com/index.aspxSt LouisWolters Kluwer HealthAccessed December 29, 2012
   Google Scholar
• King PharmaceuticalsAvinza (morphine sulfate extended-release capsules): US prescribing informationBristol (TN)King Pharmaceuticals2008
   Google Scholar
• King PharmaceuticalsEmbeda (morphine sulfate and naltrexone hydrochloride) extended-release capsules: US prescribing informationBristol (TN)King Pharmaceuticals2012
   Google Scholar
• Actavis ElizabethKadian (morphine sulfate) extended-release capsules: US prescribing informationMorristown (NJ)Actavis Elizabeth2012
   Google Scholar
• Purdue PharmaMS Contin (morphine sulfate controlled-release) tablets: US prescribing informationStamford (CT)Purdue Pharma2009
   Google Scholar
• Xanodyne PharmaceuticalsOramorph SR (morphine sulfate) tablets: US prescribing informationNewport (KY)Xanodyne Pharmaceuticals2006
   Google Scholar
• Endo PharmaceuticalsOpana ER (oxymorphone hydrochloride) extended-release tablets: US prescribing informationChadds Ford (PA)Endo Pharmaceuticals2012
   Google Scholar
• Mallinckrodt Brand PharmaceuticalsExalgo (hydromorphone hydrochloride) extended-release tablets: US prescribing informationHazelwood (MO)Mallinckrodt Brand Pharmaceuticals2012
   Google Scholar
• Janssen PharmaceuticalsNucynta ER (tapentadol) extended-release oral tablets: US prescribing informationTitusville (NJ)Janssen Pharmaceuticals2012
   Google Scholar
• Purdue PharmaOxyContin (oxycodone hydrochloride controlled-release) tablets: US prescribing informationStamford (CT)Purdue Pharma2012
   Google Scholar
• Roxane LaboratoriesDolophine (methadone hydrochloride) tablets: US prescribing informationColumbus (OH)Roxane Laboratories2012
   Google Scholar
• Mallinckrodt Brand PharmaceuticalsMethadose oral tablets (methadone hydrochloride tablets USP): US prescribing informationHazelwood (MO)Mallinckrodt Brand Pharmaceuticals2012
   Google Scholar
• Janssen PharmaceuticalsDuragesic (fentanyl transdermal system): US prescribing informationTitusville (NJ)Janssen Pharmaceuticals2012
   Google Scholar
• Purdue PharmaButrans (buprenorphine) transdermal system: US prescribing informationStamford (CT)Purdue Pharma2012
   Google Scholar
• KnotkovaHFinePGPortenoyRKOpioid rotation: the science and the limitations of the equianalgesic dose tableJ Pain Symptom Manage20093842643919735903
   PubMed Web of Science ®Google Scholar
• AdamsEHChwieckoPAce-WagonerYA study of Avinza (morphine sulfate extended-release capsules) for chronic moderate-to-severe noncancer pan conducted under real-world treatment conditions –the ACCPT StudyPain Pract2006625426417129306
   PubMedGoogle Scholar
• CaldwellJRRapoportRJDavisJCEfficacy and safety of a once-daily morphine formulation in chronic, moderate-to-severe osteoarthritis pain: results from a randomized, placebo-controlled, double-blind trial and an open-label extension trialJ Pain Symptom Manage20022327829111997197
   PubMed Web of Science ®Google Scholar
• MatsumotoAKOral extended-release oxymorphone: a new choice for chronic pain reliefExpert Opin Pharmacother200781515152717661733
   PubMed Web of Science ®Google Scholar
• HaleMEDvergstenCGimbelJEfficacy and safety of oxymorphone extended release in chronic low back pain: results of a randomized, double-blind, placebo- and active-controlled phase III studyJ Pain20056212815629415
   PubMed Web of Science ®Google Scholar
• BenedekIHJobesJXiangQFiskeWDBioequivalence of oxymorphone extended release and crush-resistant oxymorphone extended releaseDrug Design Devel Ther20115455463
   PubMed Web of Science ®Google Scholar
• FiskeWDJobesJXiangQChangSCBenedekIHThe effects of ethanol on the bioavailability of oxymorphone extended-release tablets and oxymorphone crush-resistant extended-release tabletsJ Pain201213909922208805
   PubMed Web of Science ®Google Scholar
• MooreKTSt-FleurDMarriccoNCSteady-state pharmacokinetics of extended-release hydromorphone (OROS hydromorphone): a randomized study in healthy volunteersJ Opioid Manag2010635135821046932
   PubMedGoogle Scholar
• WallaceMRauckRLMoulinDThipphawongJKhannaSTudorICOnce-daily OROS hydromorphone for the management of chronic nonmalignant pain: a dose-conversion and titration studyInt J Clin Pract2007611671167617877652
   PubMed Web of Science ®Google Scholar
• LussierDRicharzUFincoGUse of hydromorphone, with particular reference to the OROS formulation, in the elderlyDrugs Aging20102732733520361803
   PubMed Web of Science ®Google Scholar
• SathyanGXuEThipphawongJGuptaSKPharmacokinetic investigation of dose proportionality with a 24-hour controlled-release formulation of hydromorphoneBMC Clin Pharmacol20077317270058
   PubMedGoogle Scholar
• PandePHinesJWBrogranAPTamper-resistant properties of once-daily hydromorphone ER (OROS hydromorphone ER)Paper presented at the American Pain Society 30th Annual Scientific MeetingMay 19–21, 2011Austin, USA
   Google Scholar
• WallaceMRauckRLMoulinDThipphawongJKhannaSTudorICConversion from standard opioid therapy to once-daily oral extended-release hydromorphone in patients with chronic cancer painJ Internat Med Res200836343352
   PubMed Web of Science ®Google Scholar
• HartrickCTRozekRJTapentadol in pain management: a mu-opioid receptor agonist and noradrenaline reuptake inhibitorCNS Drugs20112535937021476608
   PubMed Web of Science ®Google Scholar
• HartrickCTRodriguez HernandezJRTapentadol for pain: a treatment evaluationExpert Opin Pharmacother20121328328622192161
   PubMed Web of Science ®Google Scholar
• RiemsmaRForbesCHarkerJSystematic review of tapentadol in chronic severe painCurr Med Res Opin2011271907193021905968
   PubMed Web of Science ®Google Scholar
• VadiveluNTimchenkoAHuangYSinatraRTapentadol extended-release for treatment of chronic pain: a reviewJ Pain Res2011421121821887118
   PubMedGoogle Scholar
• EtropolskiMKellyKOkamotoARauschkolbCComparable efficacy and superior gastrointestinal tolerability (nausea, vomiting, constipation) of tapentadol compared with oxycodone hydrochlorideAdv Ther201128410417
   Web of Science ®Google Scholar
• CepedaMSSuttonAWeinsteinRKimMEffect of tapentadol extended release on productivity: results from an analysis combining evidence from multiple sourcesClin J Pain20122881321646907
   PubMed Web of Science ®Google Scholar
• ToombsJDKralLAMethadone treatment for pain statesAm Fam Physician2005711353135815832538
   PubMed Web of Science ®Google Scholar
• WebsterLRCochellaSDasguptaNAn analysis of the root causes for opioid-related overdose deaths in the United StatesPain Med201112Suppl 2S26S3521668754
   PubMed Web of Science ®Google Scholar
• MuijsersRBRWagstaffAJTransdermal fentanyl: an updated review of its pharmacological properties and therapeutic efficacy in chronic cancer pain controlDrugs2001612289230711772140
   PubMed Web of Science ®Google Scholar
• HansGRobertDTransdermal buprenorphine – a critical appraisal of its role in pain managementJ Pain Res2009211713421197300
   PubMedGoogle Scholar
• NelsonLSchwanerRTransdermal fentanyl: pharmacology and toxicologyJ Med Toxicol2009523024119876859
   PubMedGoogle Scholar
• HairPIKeatingGMMcKeageKTransdermal matrix fentanyl membrane patch (Matrifen) in severe cancer-related chronic painDrugs2008682001200918778121
   PubMed Web of Science ®Google Scholar
• MarierJ-FLorMMorinJComparative bioequivalence study between a novel matrix transdermal delivery system of fentanyl and a commercially available reservoir formulationBr J Clin Pharmacol20066312112416939522
   PubMed Web of Science ®Google Scholar
• MooreKTAdamsHDNatarajanJAriyawansaJRichardsHMBioequivalence and safety of a novel fentanyl transdermal matrix system compared with a transdermal reservoir systemJ Opioid Manag201179910721561033
   PubMedGoogle Scholar
• [No authors listed]Fentanyl patches: preventable overdosePrescrire Int201019222520455338
   PubMedGoogle Scholar
• MooreKTSathyanGRicharzUNatarajanJVandenbosscheJRandomized 5-treatment crossover study to assess the effects of external heat on serum fentanyl concentrations during treatment with transdermal fentanyl systemsJ Clin Pharmacol2011521174118521878578
   PubMed Web of Science ®Google Scholar
• ColeJMBestBMPesceAJVariability of transdermal fentanyl metabolism and excretion in pain patientsJ Opioid Manag20106293920297612
   PubMedGoogle Scholar
• PloskerGLBuprenorphine 5, 10, and 20 micrograms/h transdermal patch: a review of its use in the management of chronic non-malignant painDrugs2011712491250922141389
   PubMed Web of Science ®Google Scholar
• CowanALewisJWMacfarlaneIRAgonist and antagonist properties of buprenorphine: a new antinociceptive agentBr J Pharmacol197760537545409448
   PubMed Web of Science ®Google Scholar
• SchutterURitzdorfIHeckesBThe transdermal 7-day buprenorphine patch – an effective and safe treatment of pain if tramadol or tilidate/naloxone is insufficient. Results of a non-interventional studyMMW Fortschr Med2010152Suppl 26269 German21591321
   PubMedGoogle Scholar
• SteinerDMuneraCHaleMRipaSLandauCEfficacy and safety of buprenorphine transdermal system (BTDS) for chronic moderate to severe low back pain: a randomized, double-blind studyJ Pain2011121163117321807566
   PubMed Web of Science ®Google Scholar
• SteinerDJSitarSWenWEfficacy and safety of the seven-day buprenorphine transdermal system in opiate-naïve patients with moderate to severe chronic low back pain: an enriched, randomized, double-blind, placebo-controlled studyJ Pain Symptom Manage20114290391721945130
   PubMed Web of Science ®Google Scholar
• NordboASkurtveitSBorchgrevinkPCKaasaSFredheimOMLow-dose transdermal buprenorphine – long-term use and co-medication with other potentially addictive drugsActa Anaesthesiol Scand201256889422092357
   PubMed Web of Science ®Google Scholar
• McCrackenLMIversonGLDisrupted sleep patterns and daily functioning in patients with chronic painPain Res Manag20027757912185371
   PubMedGoogle Scholar
• KosinskiMJaganapCGajriaKScheinJFreedmanJPain relief and pain-related sleep disturbance with extended-release tramadol in patients with osteoarthritisCurr Med Res Opin2007231615162617559754
   PubMed Web of Science ®Google Scholar
• TangNKWrightKJSalkovskisPMPrevalence and correlates of clinical insomnia co-occurring with chronic back painJ Sleep Res200716859517309767
   PubMed Web of Science ®Google Scholar
• BinsfeldHSzczepanskiLWaechterSRicharzUSabatowskiRA randomized study to demonstrate noninferiority of once-daily OROS hydromorphone with twice-daily sustained-release oxycodone for moderate to severe chronic noncancer painPain Pract20101040441520384968
   PubMed Web of Science ®Google Scholar
• RauckRLWhat is the case for prescribing long-acting opioids over short-acting opioids for patients with chronic pain? A critical reviewPain Pract2009946847919874536
   PubMed Web of Science ®Google Scholar
• RosenthalMMoorePGrovesESleep improves when patients with chronic OA pain are managed with morning dosing of once a day extended-release morphine sulfate (Avinza): findings from a pilot studyJ Opioid Manag2007314515418027540
   PubMedGoogle Scholar
• SittlRTransdermal buprenorphine in the treatment of chronic painExpert Rev Neurother2005531532315938664
   PubMedGoogle Scholar
• KornickCASantiago-PalmaJMorylNPayneRObbensEABenefit-risk assessment of transdermal fentanyl for the treatment of chronic painDrug Saf20032695197314583070
   PubMed Web of Science ®Google Scholar
• RauckRLBookbinderSABunkerTRA randomized, open-label, multicenter trial comparing once-a-day Avinza (morphine sulfate extended-release capsules) versus twice-a-day OxyContin (oxycodone hydrochloride controlled-release tablets) for the treatment of chronic, moderate to severe low back pain: improved physical functioning in the ACTION trialJ Opioid Manag20073354317367093
   PubMedGoogle Scholar
• GraziottinAGardner-NixJStumpfMBerlinerMNOpioids: how to improve compliance and adherencePain Pract20111157458121410639
   PubMed Web of Science ®Google Scholar
• US Food and Drug AdministrationRisk evaluation and mitigation strategies (REMS) for extended-release and long-acting opioids2012 Available from: http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM311290.pdfAccessed November 21, 2012
   Google Scholar
• SmithHBruckenthalPImplications of opioid analgesia for medically complicated patientsDrugs Aging20102741743320450239
   PubMed Web of Science ®Google Scholar
• DosaDMDoreDDMorVTenoJMFrequency of long-acting opioid analgesic initiation in opioid-naïve nursing home residentsJ Pain Symptom Manage20093851552119375273
   PubMed Web of Science ®Google Scholar
• RazaqMBalicasMMankanNUse of hydromorphone (Dilaudid) and morphine for patients with hepatic and renal impairmentAm J Ther20071441441617667220
   PubMedGoogle Scholar
• PergolizziJVJrLabhsetwarSAPuenpatomRAJooSBen-JosephRHSummersKHPrevalence of exposure to potential CYP450 pharmacokinetic drug–drug interactions among patients with chronic low back pain taking opioidsPain Pract20111123023920807350
   PubMed Web of Science ®Google Scholar
• PeacockWFHollanderJEDiercksDBMorphine and outcomes in acute decompensated heart failure: an ADHERE analysisEmerg Med J20082520520918356349
   PubMed Web of Science ®Google Scholar
• GruberEMTschernkoEMAnaesthesia and postoperative analgesia in older patients with chronic obstructive analgesia in older patients with chronic obstructive pulmonary disease: special considerationsDrugs Aging20032034736012696995
   PubMed Web of Science ®Google Scholar
• BellvilleJWEscarragaLAWallensteinSLRelative respiratory depressant effects of oxymorphone (Numorphan) and morphineAnesthesiology19602139740013798620
   PubMed Web of Science ®Google Scholar
• MurtaghFEChaiMODonohoePThe use of opioid analgesia in end-stage renal disease patients managed without dialysis: recommendations for practiceJ Pain Palliat Care Pharmacother20072151617844723
   PubMedGoogle Scholar
• TegederILotschJGeisslingerGPharmacokinetics of opioids in liver diseaseClin Pharmacokinet199937174010451781
   PubMed Web of Science ®Google Scholar
• Purdue PharmaDilaudid (hydromorphone hydrochloride) oral liquid and tablets: US prescribing informationStamford (CT)Purdue Pharma2008
   Google Scholar
• WolffJBiglerDChristensenCBInfluence of renal function on the elimination of morphine and morphine glucoronidesEur J Clin Pharmacol1988343533573402521
   PubMed Web of Science ®Google Scholar
• BabulNDurkeACHagenNHydromorphone metabolite accumulation in renal failureJ Pain Symptom Manage1995101841867543126
   PubMed Web of Science ®Google Scholar
• GuayDRAwniWMFindlayJWPhamacokinetics and pharmacodynamics of codeine in end-stage renal diseaseClin Pharmacol Ther19884363713335120
   PubMed Web of Science ®Google Scholar
• BarkinRLExtended-release tramadol (Ultram ER): a pharmacotherapeutic, pharmacokinetic, and pharmacodynamics focus on effectiveness and safety in patients with chronic/persistent painAm J Ther20081515716618356636
   PubMed Web of Science ®Google Scholar
• Parsells KellyJCookSFKaufmanDWPrevalence and characteristics of opioid use in the US adult populationPain200813850751318342447
   PubMed Web of Science ®Google Scholar
• JansàMHernándezCVidalMMultidimensional analysis of treatment adherence in patients with multiple chronic conditions. A cross-sectional study in a tertiary hospitalPatient Educ Couns20108116116820167450
   PubMed Web of Science ®Google Scholar
• FosterAMobleyEWangZComplicated pain management in a CYP4502D6 poor metabolizerPain Pract2007735235617986163
   PubMedGoogle Scholar
• SusceMTMurray-CarmichaelEDe LeonJResponse to hydrocodone, codeine and oxycodone in a CYP2D6 poor metabolizerProg Neuropsychopharmacol Biol Psychiatry2005301356135816631290
   PubMed Web of Science ®Google Scholar
• SmithHSOpioid metabolismMayo Clin Proc20098461362419567715
   PubMed Web of Science ®Google Scholar
• AdamsMPieniaszekHJJrGammaitoniAROxymorphone extended release does not affect CYP2C9 or CCYP3A4 metabolic pathwaysJ Clin Pharmacol20054533734515703368
   PubMed Web of Science ®Google Scholar
• CoffmanBLRiosGRKingCDHuman UGT287 catalyzes morphine glucuronidationDrug Metab Dispos199725149010622
   PubMed Web of Science ®Google Scholar
• De WildtSNKearnsGLLeederJSGlucoronidation in humans: pharmacogenetic and developmental aspectsClin Pharmacokinet19993643945210427468
   PubMed Web of Science ®Google Scholar
• SinatraROpioid analgesics in primary care: challenges and new advances in the management of noncancer painJ Am Board Fam Med20061916517716513905
   PubMed Web of Science ®Google Scholar
• SathyanGSivakumarKThipphawongJPharmacokinetic profile of a 24-hour controlled-release OROS formulation of hydromorphone in the presence of alcoholCurr Med Res Opin20082429730518062845
   PubMed Web of Science ®Google Scholar
• US Food Drug AdministrationFDA alert. Alcohol–Palladone interaction Available from: http://www.fda.gov/Drugs/Drug-Safety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm129288.htmAccessed January 28, 2013
   Google Scholar
• WaldenMNichollsFASmithKJTuckerGTThe effect of ethanol on the release of opioids from oral prolonged-release preparationsDrug Devel Indust Pharm20073311011111
   PubMed Web of Science ®Google Scholar
• BarkinRLShiraziDKinzlerEEffect of ethanol on the release of morphine sulfate from Oramorph SR tabletsAm J Ther20091648248619770796
   PubMed Web of Science ®Google Scholar
• JohnsonFWagnerGSunSStaufferJEffect of concomitant ingestion of alcohol on the in vivo pharmacokinetics of Kadian (morphine sulfate extended-release) capsulesJ Pain2008933033618201934
   PubMed Web of Science ®Google Scholar
• GuayDROral hydromorphone extended-releaseConsult Pharm20102581682821172762
   PubMedGoogle Scholar
• GourlayDLHeitHAAlmahreziAUniversal precautions in pain medicine: a rational approach to the treatment of chronic painPain Med2005610711215773874
   PubMed Web of Science ®Google Scholar
• WebsterLRWebsterRMPredicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid Risk ToolPain Med200569643244216336480
   PubMed Web of Science ®Google Scholar
• ButlerSFBudmanSHFernandezKCFanciulloGJJamisonRNCross-validation of a screener to predict opioid misuse in chronic pain patients (SOAPP-R)J Addict Med20093667320161199
   PubMed Web of Science ®Google Scholar
• PassikSDKirshKLWhitcombLA new tool to assess and document pain outcomes in chronic pain patients receiving opioid therapyClin Ther20042655256115189752
   PubMed Web of Science ®Google Scholar
• EdlundMJSteffickDHudsonTRisk factors for clinically recognized opioid abuse and dependence among veterans using opioids for chronic non-cancer painPain200712835536217449178
   PubMed Web of Science ®Google Scholar
• ZangerUMRaimundoSEichelbaumMCytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistryNaunyn Schmiedebergs Arch Pharmacol2004369233714618296
   PubMed Web of Science ®Google Scholar
• ZhouSFPolymorphism of human cytochrome P450 2D6 and its clinical significance: part 1Clin Pharmacokinet20094868972319817501
   PubMed Web of Science ®Google Scholar
• KirchheinerJSchmidtHTzvetkovMPharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplicationPharmacogenomics J2007725726516819548
   PubMed Web of Science ®Google Scholar
• Quang-CantagrelNDWallaceMSMagnusonSKOpioid substitution to improve the effectiveness of chronic noncancer pain control: a chart reviewAnesth Analg20009093393710735802
   PubMed Web of Science ®Google Scholar
• KatzNFanciulloGJRole of urine toxicology testing in the management of chronic opioid therapyClin J Pain200218S76S8212479257
   PubMed Web of Science ®Google Scholar
• ManchikantiLAtluriSTrescotAMGiordanoJMonitoring opioid adherence in chronic pain patients: tools, techniques, and utilityPain Physician200811S155S18018443638
   PubMed Web of Science ®Google Scholar
• WoolfCJHashmiMUse and abuse of opioid analgesics: potential methods to prevent and deter non-medical consumption of prescription opioidsCurr Opin Investig Drugs200456166
   PubMedGoogle Scholar
• US Food and Drug AdministrationJoint meeting of the Anesthetic and Life Support Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee: Risk Evaluation and Mitigation Strategies (REMS) for extended-release and long-acting opioid analgesics2010 Available from: http://www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/ucm217510.pdfAccessed September 6, 2012
   Google Scholar
• Substance Abuse and Mental Health Services AdministrationResults from the 2010 National Survey on Drug Use and Health: Summary of National FindingsRockville (MD)Office of Applied Studies2011 Available from: http://www.samhsa.gov/data/nsduh/2k10nsduh/2k10results.htmAccessed July 30, 2012
   Google Scholar
• ManchikantiLSinghATherapeutic opioids: a ten-year perspective on the complexities and complications of the escalating use, abuse, and nonmedical use of opioidsPain Physician200811S63S8818443641
   PubMed Web of Science ®Google Scholar
• McCabeSECranfordJABoydCJTeterCJMotives, diversion and routes of administration associated with nonmedical use of prescription opioidsAddict Behav20073256257516843611
   PubMed Web of Science ®Google Scholar
• CoutoJERomneyMCLeiderHLSharmaSGoldfarbNIHigh rates of inappropriate drug use in the chronic pain populationPopul Health Manag20091218519019663620
   PubMed Web of Science ®Google Scholar
• ChabalCErjavecMKJacobsonLMarianoAChaneyEPrescription opiate abuse in chronic pain patients: clinical criteria, incidence, and predictorsClin J Pain1997131501559186022
   PubMed Web of Science ®Google Scholar
• ManchikantiLPampatiVDamronKSFellowsBBarnhillRCBeyerCPrevalence of opioid abuse in interventional pain medicine practice settings: a randomized clinical evaluationPain Physician2001435836516902682
   PubMedGoogle Scholar
• KatzNPSherburneSBeachMBehavioral monitoring and urine toxicology testing in patients receiving long-term opioid therapyAnesth Analg2003971097110214500164
   PubMed Web of Science ®Google Scholar
• FlemingMFBalousekSLKlessigCLMundtMPBrownDDSubstance use disorders in a primary care sample receiving daily opioid therapyJ Pain2007857358217499555
   PubMed Web of Science ®Google Scholar
• WebsterLRBathBMedveRAOpioid formulations in development designed to curtail abuse: who is the target?Expert Opin Investig Drugs200918255263
   PubMed Web of Science ®Google Scholar
• KatzNDartRCBaileyETrudeauJOsgoodEPaillardFTampering with prescription opioids: nature and extent of the problem, health consequences, and solutionsAm J Drug Alcohol Abuse20113720521921517709
   PubMed Web of Science ®Google Scholar
• CariseDDugoshKLMcLellanATCamilleriAWoodyGELynchKGPrescription OxyContin abuse among patients entering addiction treatmentAm J Psychiatry20071641750175617974941
   PubMed Web of Science ®Google Scholar
• YoungAMHavensJRLeukefeldCGRoute of administration for illicit prescription opioids: a comparison of rural and urban drug usersHarm Reduct J201072420950455
   PubMed Web of Science ®Google Scholar
• McClellanATTurnerBJChronic noncancer pain management and opioid overdose: time to change prescribing practicesAnn Intern Med201015212312520083830
   PubMed Web of Science ®Google Scholar
• CarrollCPHaythornthwaiteJMaladaptive opioid use behaviors and psychiatric illness: what should we do with what we know?Curr Pain Headache Rep201115919321274661
   PubMed Web of Science ®Google Scholar
• JackmanRPPurvisJMMallettBSChronic nonmalignant pain in primary careAm Fam Physician20087811551162116419035063
   PubMed Web of Science ®Google Scholar
• WuLTWoodyGEYangCMannelliPBlazerDGDifferences in onset and abuse/dependence episodes between prescription opioids and heroin: results from the national Epidemiologic Survey on Alcohol and Related ConditionsSubst Abuse Rehabil20112011778821686045
   PubMedGoogle Scholar
• NBC NewsHow Florida brothers’ ‘pill mill’ operation fueled painkiller abuse epidemic [comments]2012 Available from: http://openchannel.msnbc.msn.com/_news/2012/05/07/11542417-how-florida-brothers-pill-mill-operation-fueled-painkiller-abuse-epidemic#commentsAccessed December 29, 2012
   Google Scholar
• FarreMCamiJPharmacokinetic considerations in abuse liability evaluationBr J Addict199186160116061786493
   PubMedGoogle Scholar
• ComerSDAshworthJBSullivanMAVosburgSKSacconePAFoltinRWRelationship between rate of infusion and reinforcing strength of oxycodone in humansJ Opioid Manag2009520321219736900
   PubMedGoogle Scholar
• ButlerSFFernandezKCChangAMeasuring attractiveness for abuse of prescription opioidsPain Med201011678020002325
   PubMed Web of Science ®Google Scholar
• WebsterLRBathBMedveRAMarmonTStoddardGJRandomized, double-blind, placebo-controlled study of the abuse potential of different formulations of oral oxycodonePain Med20121379080122568663
   PubMed Web of Science ®Google Scholar
• KatzNAbuse-deterrent opioid formulations: are they a pipe dream?Curr Rheumatol Rep200810111818457606
   PubMedGoogle Scholar
• BudmanSHSerranoJMGButlerSFCan abuse deterrent formulations make a difference? Expectation and speculationHarm Reduct J2009681519480676
   PubMed Web of Science ®Google Scholar
• JohnsonFSetnikBMorphine sulfate and naltrexone hydrochloride extended-release capsules: naltrexone release, pharmacodynamics, and tolerabilityPain Physician20111439140621785483
   PubMed Web of Science ®Google Scholar
• RegenceRxTherapeutic class review: pain-long-acting opioids2010 Available from: http://www.regencerx.com/docs/physicianRx/pain-long-acting-0410.pdfAccessed December 29, 2012
   Google Scholar
• US Food and Drug AdministrationFDA approves new formulation for OxyContin2010 Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2010/ucm207480.htmAccessed September 6, 2012
   Google Scholar
• LingWMooneyLHillhouseMPrescription opioid abuse, pain and addiction: clinical issues and implicationsDrug Alcohol Rev20113030030521545561
   PubMed Web of Science ®Google Scholar
• Office of National Drug Control PolicyPrescription drug abuse prevention plan2011 Available from: http://www.whitehouse.gov/sites/default/files/ondcp/issues-content/prescription-drugs/rx_abuse_plan.pdfAccessed January 28, 2013
   Google Scholar
• US Food and Drug AdministrationMedication disposal: questions and answers2009 Available from: http://www.fda.gov/Drugs/ResourcesForYou/Consumers/BuyingUsingMedicineSafely/EnsuringSafeUseofMedicine/SafeDisposalofMedicines/ucm186188.htmAccessed November 17, 2012
   Google Scholar